Literature DB >> 18471038

Adjuvant temozolomide: how long and how much?

Enrico Franceschi, Alicia Tosoni, Alba A Brandes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18471038     DOI： 10.1586/14737140.8.5.663

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


× No keyword cloud information.
  1 in total

1.  Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.

Authors:  C Balañá; M A Vaz; D Lopez; R de la Peñas; J M García-Bueno; M J Molina-Garrido; J M Sepúlveda; J M Cano; C Bugés; S M Sanz; J L Arranz; P Perez-Segura; A Rodriguez; J M Martin; M Benavides; M Gil
Journal:  Clin Transl Oncol       Date:  2013-06-21       Impact factor: 3.405
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.